Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 650 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 England moves to a single-dose HPV vaccine June 21, 2023 Lo que deben saber las personas con cáncer de mama y... January 4, 2024 Expressive Writing, What is It? May 12, 2021 Load more HOT NEWS Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... News digest – dinosaur bone cancer, YouTube junk food ad ban... Does Sugar Cause Cancer? FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer
